SG Americas Securities LLC Sells 16,513 Shares of AtriCure, Inc. (NASDAQ:ATRC)

SG Americas Securities LLC lowered its holdings in AtriCure, Inc. (NASDAQ:ATRCGet Rating) by 54.4% in the third quarter, HoldingsChannel.com reports. The firm owned 13,858 shares of the medical device company’s stock after selling 16,513 shares during the quarter. SG Americas Securities LLC’s holdings in AtriCure were worth $542,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Chartwell Investment Partners LLC boosted its holdings in AtriCure by 37.3% in the 3rd quarter. Chartwell Investment Partners LLC now owns 19,416 shares of the medical device company’s stock valued at $759,000 after purchasing an additional 5,272 shares during the period. Truist Financial Corp lifted its holdings in shares of AtriCure by 6.3% during the 3rd quarter. Truist Financial Corp now owns 26,597 shares of the medical device company’s stock worth $1,041,000 after acquiring an additional 1,574 shares during the period. Granite Investment Partners LLC lifted its holdings in shares of AtriCure by 83.7% during the 3rd quarter. Granite Investment Partners LLC now owns 407,191 shares of the medical device company’s stock worth $15,921,000 after acquiring an additional 185,481 shares during the period. WCM Investment Management LLC lifted its holdings in shares of AtriCure by 3.7% during the 3rd quarter. WCM Investment Management LLC now owns 192,247 shares of the medical device company’s stock worth $7,601,000 after acquiring an additional 6,774 shares during the period. Finally, Diversified Trust Co lifted its holdings in shares of AtriCure by 24.8% during the 3rd quarter. Diversified Trust Co now owns 12,072 shares of the medical device company’s stock worth $472,000 after acquiring an additional 2,397 shares during the period. Institutional investors own 95.27% of the company’s stock.

AtriCure Price Performance

ATRC stock opened at $43.11 on Tuesday. The company has a 50 day simple moving average of $44.01 and a 200 day simple moving average of $43.78. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -35.34 and a beta of 1.24. AtriCure, Inc. has a 1 year low of $32.51 and a 1 year high of $72.31. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.69 and a quick ratio of 2.92.

AtriCure (NASDAQ:ATRCGet Rating) last announced its quarterly earnings results on Tuesday, November 1st. The medical device company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.02). AtriCure had a negative net margin of 17.76% and a negative return on equity of 12.09%. The business had revenue of $83.25 million during the quarter, compared to analyst estimates of $81.40 million. Research analysts anticipate that AtriCure, Inc. will post -1.1 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. BTIG Research cut their price target on shares of AtriCure from $75.00 to $71.00 and set a “buy” rating for the company in a report on Monday, October 17th. Needham & Company LLC upped their price target on shares of AtriCure from $55.00 to $58.00 and gave the stock a “buy” rating in a report on Monday, December 19th. TheStreet downgraded shares of AtriCure from a “c-” rating to a “d” rating in a report on Tuesday, November 1st. Canaccord Genuity Group cut their price target on shares of AtriCure from $72.00 to $65.00 in a report on Wednesday, November 2nd. Finally, StockNews.com upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research report on Tuesday, January 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $60.67.

AtriCure Profile

(Get Rating)

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.

Read More

Want to see what other hedge funds are holding ATRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AtriCure, Inc. (NASDAQ:ATRCGet Rating).

Institutional Ownership by Quarter for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.